JP2022529266A5 - - Google Patents

Info

Publication number
JP2022529266A5
JP2022529266A5 JP2021561000A JP2021561000A JP2022529266A5 JP 2022529266 A5 JP2022529266 A5 JP 2022529266A5 JP 2021561000 A JP2021561000 A JP 2021561000A JP 2021561000 A JP2021561000 A JP 2021561000A JP 2022529266 A5 JP2022529266 A5 JP 2022529266A5
Authority
JP
Japan
Prior art keywords
antibody
composition according
week
pharmaceutical composition
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021561000A
Other languages
English (en)
Japanese (ja)
Other versions
JP7628962B2 (ja
JP2022529266A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/053565 external-priority patent/WO2020212874A1/en
Publication of JP2022529266A publication Critical patent/JP2022529266A/ja
Publication of JP2022529266A5 publication Critical patent/JP2022529266A5/ja
Priority to JP2025013906A priority Critical patent/JP2025069284A/ja
Application granted granted Critical
Publication of JP7628962B2 publication Critical patent/JP7628962B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021561000A 2019-04-15 2020-04-15 乾癬性関節炎に罹患している対象者の治療方法 Active JP7628962B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025013906A JP2025069284A (ja) 2019-04-15 2025-01-30 乾癬性関節炎に罹患している対象者の治療方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201921015050 2019-04-15
IN201921015050 2019-04-15
IN202021004422 2020-01-31
IN202021004422 2020-01-31
PCT/IB2020/053565 WO2020212874A1 (en) 2019-04-15 2020-04-15 Methods for treatment of subjects with psoriatic arthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025013906A Division JP2025069284A (ja) 2019-04-15 2025-01-30 乾癬性関節炎に罹患している対象者の治療方法

Publications (3)

Publication Number Publication Date
JP2022529266A JP2022529266A (ja) 2022-06-20
JP2022529266A5 true JP2022529266A5 (https=) 2023-04-20
JP7628962B2 JP7628962B2 (ja) 2025-02-12

Family

ID=72837755

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021561000A Active JP7628962B2 (ja) 2019-04-15 2020-04-15 乾癬性関節炎に罹患している対象者の治療方法
JP2025013906A Pending JP2025069284A (ja) 2019-04-15 2025-01-30 乾癬性関節炎に罹患している対象者の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025013906A Pending JP2025069284A (ja) 2019-04-15 2025-01-30 乾癬性関節炎に罹患している対象者の治療方法

Country Status (16)

Country Link
US (1) US20220298233A1 (https=)
EP (1) EP3956357A4 (https=)
JP (2) JP7628962B2 (https=)
KR (1) KR20210140780A (https=)
CN (1) CN113825768A (https=)
AU (1) AU2020259375A1 (https=)
BR (1) BR112021020612A2 (https=)
CA (1) CA3143604A1 (https=)
IL (1) IL287213A (https=)
JO (1) JOP20210279A1 (https=)
MA (1) MA55729A (https=)
MX (1) MX2021012652A (https=)
MY (1) MY210310A (https=)
PH (1) PH12021552536A1 (https=)
SG (1) SG11202111056YA (https=)
WO (1) WO2020212874A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121843958A (zh) * 2023-08-11 2026-04-10 信达生物医药科技(杭州)有限公司 既往接受生物制剂治疗斑块状银屑病的受试者转用抗IL23p19抗体治疗斑块状银屑病的方法
AU2024338774A1 (en) * 2023-09-07 2026-03-26 Innovent Biologics (Suzhou) Co., Ltd. Method for treating moderate and severe psoriasis using recombinant anti-il-23p19 antibody
WO2026069253A1 (en) * 2024-09-30 2026-04-02 Sun Pharmaceutical Industries Limited Long term safety of tildrakizumab in psoriatic arthritis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807389B2 (en) * 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
WO2008063213A2 (en) * 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
ES2708988T3 (es) * 2007-02-23 2019-04-12 Merck Sharp & Dohme Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética
EP2331078B1 (en) * 2008-08-27 2012-09-19 Merck Sharp & Dohme Corp. Lyophilized formulations of engineered anti-il-23p19 antibodies
MX2019000046A (es) * 2010-11-04 2023-10-05 Boehringer Ingelheim Int Anticuerpos anti-il-23.
ES2729603T3 (es) * 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19

Similar Documents

Publication Publication Date Title
US20240417455A1 (en) Treatment for rheumatoid arthritis
JP2025172841A5 (https=)
JP2024075713A5 (https=)
JP2022529266A5 (https=)
JP2021523188A5 (https=)
JP2021517566A5 (https=)
US20010026801A1 (en) Cytokine antagonists for the treatment of localized disorders
JP2021193121A (ja) Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法
JP2025102888A (ja) Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
JP2024102205A5 (https=)
JP2024510588A5 (https=)
JP2022545967A5 (https=)
JP2020535149A5 (https=)
JP2021514003A5 (https=)
JP2019507775A5 (https=)
JP2018535961A5 (https=)
JP2022536088A5 (https=)
JP2025069284A5 (https=)
JP2022544053A5 (https=)
JP2024532263A5 (https=)
JP2007119497A (ja) インターフェロン−ガンマスティミュレーター含有医薬組成物
JP2021523881A5 (https=)
US20020025316A1 (en) Pharmaceutical composition containing inhibitors of interferon-gamma
JPS5967226A (ja) ウイルス感染処置に使用する転移因子
JP2022514561A5 (https=)